EditorialEditorial

Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF

Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299

Article Information

vol. 19 no. 7 945-947
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2022.0299
Published By 
Cancer Biology & Medicine
History 
  • Received June 2, 2022
  • Accepted June 15, 2022
  • Published online July 27, 2022.
Copyright & Usage 
Copyright: © 2022, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section